Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

Home

BJDX

B

Bluejay Diagnostics, Inc. (BJDX)

NCM – Real Time Price. Currency in USD

1.96

-0.02 (-1.01%)

At close: Mar 27, 2026, 4:00 PM EDT

1.85

-0.11 (-5.61%)

After-hours: Mar 27, 2026, 4:09 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting

Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting

New clinical data from the SYMON-I study to evaluate IL-6 and organ dysfunction in sepsis patients to be presented. New clinical data from the SYMON-I study to evaluate IL-6 and organ dysfunction in sepsis patients to be presented.

NorthStrive Fund II LP Issues Open Letter to the Board and Shareholders of Bluejay Diagnostics

NorthStrive Fund II LP Issues Open Letter to the Board and Shareholders of Bluejay Diagnostics

NEWPORT BEACH, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- NorthStrive Fund II LP (“NorthStrive Fund”), a subsidiary of NorthStrive Companies Inc., today issued an open letter to the Board of Directors and shareholders of Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”) recommending the Board evaluate a strategic opportunity that NorthStrive believes could significantly enhance long-term shareholder value.

Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised

Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised

ACTON, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ: BJDX) today announced that as of February 19, 2026, all of the prefunded warrants issued by the Company in its October 2025 private placement have been fully exercised, and the Company has no remaining prefunded warrants of any class or tranche outstanding. Following these exercises, the Company now has approximately 972,000 shares of common stock outstanding. In addition, the Company has cash exercisable warrants outstanding for approximately 1.5 million shares. All such warrants have a cash exercise price of $7.00 or greater per share.

Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026

Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026

ACTON, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ: BJDX) today announced that it has successfully enrolled 545 patients in its SYMON™ II multicenter clinical study and has made substantial progress in advancing manufacturing readiness and technology transfer initiatives into 2026, representing a key execution milestone as the Company transitions from clinical enrollment toward data analysis, regulatory engagement, and commercialization readiness.

Bluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody Production

Bluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody Production

ACTON, Mass., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”) announced that it has completed commercial-scale production of both polyclonal and monoclonal antibodies targeting interleukin-6 (IL-6), a biomarker relevant to inflammatory and critical-care applications.

Bluejay Diagnostics Provides Second Quarter Business and Corporate Update

Bluejay Diagnostics Provides Second Quarter Business and Corporate Update

ACTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing near-patient solutions for critical care, today announced financial results for the quarter ended June 30, 2025, and provided an update on its Symphony IL-6 test program and key operational milestones.

Videos

No Data

There is no data to display